BRD4 and neoplasm: Treatment with the BET-bromodomain inhibitor in tumor cells markedly reduced BRD4, Mediator, and P-TEFb levels at SEs and consequent transcription elongation defects that preferentially impacted genes with SEs (Lovén et al., 2013).